28 stories found
Extended and midday trading sessions saw significant price swings across multiple sectors, with notable movements reported for Snowflake, Tesla, Meta, and biotech firms following corporate developments and macroeconomic shifts.
S&P 500 futures edged higher in premarket trading as investors parsed earnings reports from Broadcom, HPE, Snowflake, and Ultragenyx, with Snowflake and Netskope among the leaders.
Evercore ISI reiterated NetApp stock rating on strong Q1 results and cut Ultragenyx on trial failure, while advising hedges against September volatility.
Wells Fargo analysts raised their price target for Ultragenyx Pharmaceutical following positive Phase 3 trial results, citing improved therapeutic outcomes and commercial potential.
Ultragenyx has received accelerated approval for its gene therapy designed to treat glycogen storage disease. This approval marks a significant step in addressing the rare genetic disorder.
Details emerge about a fund's $5.4 million purchase of Ultragenyx shares, even as the company's stock has declined by 30% over the past year.
Ultragenyx Pharmaceutical is garnering bullish sentiment from investors in anticipation of its forthcoming GTX-102 Phase 3 trial for Angelman Syndrome, signaling confidence in its clinical development.
Ultragenyx (RARE) has announced positive results from its DTX301 Phase 3 study, marking a significant development for the company's therapeutic pipeline.
Multiple biotech and pharmaceutical companies, including Legend Biotech, Corcept Therapeutics, and Ultragenyx, have released updates on their drug pipelines, clinical trial data, and regulatory interactions, impacting market outlook.
Ultragenyx Pharmaceutical saw its stock drop sharply after announcing that a pivotal Phase 3 trial for its experimental Angelman syndrome therapy did not meet primary endpoints. Several financial analysts downgraded the company, though some investors remain optimistic about its broader pipeline.
Shares of biotech firm Ultragenyx fell significantly after its Phase 3 Aspire study failed to meet its primary efficacy endpoint.
Shares of biotech firm Ultragenyx plummeted by nearly half in intraday trading following a significant corporate disclosure that triggered severe investor sell-offs.
Shares jumped 7.5% after regulatory clearance for an ultra-rare disease treatment, raising questions about the commercial viability of high-cost personalized medicine.
This report identifies Intuit (INTU), Hamilton Lane (HLNE), and Ultragenyx Pharmaceutical (RARE) as some of the best buy-the-dip stocks. It provides reasons why these companies are considered strong investment opportunities after a market downturn.
Ultragenyx's Rare Bootcamp program provides families affected by rare diseases with a roadmap and resources to help drive research and develop new treatments.
The FDA has accepted Ultragenyx's Biologics License Application (BLA) for UX111, a gene therapy designed to treat Sanfilippo Syndrome. This acceptance moves the therapy closer to potential regulatory approval.
Ultragenyx has announced that its investigational new drug (IND) application for UX016, intended for the treatment of GNE myopathy, has received clearance from the FDA.
Ultragenyx Pharmaceutical Inc. (RARE) Investors: April 6, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP The Globe and Mail
Leading market analysts issued fresh stock recommendations, upgrading semiconductor giant Broadcom while downgrading biotech firm Ultragenyx.
Wells Fargo analysts have lowered their price target for HP Enterprise, expressing concerns over weakening revenue forecasts and challenging market conditions.
Shares of biotech firm Ultragenyx plummet following disappointing results from a late-stage clinical trial targeting Angelman syndrome, highlighting ongoing challenges in rare disease drug development.
Stifel and H.C. Wainwright have reiterated their stock ratings for several companies, including Nlight, IDEXX Laboratories, Analog Devices, Veralto, Bitdeer, UroGen Pharma, Bright Minds, Seaport Therapeutics, Ultragenyx, and Zevra Therapeutics. These reiterations are based on various factors such as limited China exposure, data center strength, new deals, and contract agreements.
Optimism for Ultragenyx Pharmaceutical (RARE) is being fueled by institutional confidence in its drug candidate, GTX-102.
Multiple companies have released their recent financial performance, detailing GAAP or Non-GAAP earnings per share and revenue figures. These reports indicate whether the companies met, beat, or missed analyst expectations for their latest reporting period.
Ultragenyx has announced that its gene therapy has been accepted for review by the FDA once again.
Ultragenyx Pharmaceutical Inc. has been downgraded to a 'neutral' rating by Goldman Sachs, following the release of new data concerning its drug setrusumab.
An analysis presents a 'Bull Case Theory' for Ultragenyx Pharmaceutical Inc. (RARE), outlining potential positive financial prospects for the company.